UY37016A - Inhibidores de la tirosina quinasa de bruton y métodos de su uso - Google Patents

Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Info

Publication number
UY37016A
UY37016A UY0001037016A UY37016A UY37016A UY 37016 A UY37016 A UY 37016A UY 0001037016 A UY0001037016 A UY 0001037016A UY 37016 A UY37016 A UY 37016A UY 37016 A UY37016 A UY 37016A
Authority
UY
Uruguay
Prior art keywords
methods
inhibitors
tyrosine kinase
bruton tyrosine
bruton
Prior art date
Application number
UY0001037016A
Other languages
English (en)
Spanish (es)
Inventor
Nidhi Arora
M Bacani Genesis
Kent Barbay Joseph
D Bembenek Scott
Min Cai
Pooley Deckhut Charlotte
Brahmananda Ghosh
Baoyu Hao
Gang Li
S Tichenor Mark
D Venable Jennifer
Jianmei Wei
J M Wiener John
Yao Wu
Yaoping Zhu
Feihuang Zhang
Zheng Zhang
Kun Xiao
Wei Chen
P Edwards James
D Kreutter Kevin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of UY37016A publication Critical patent/UY37016A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001037016A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso UY37016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10

Publications (1)

Publication Number Publication Date
UY37016A true UY37016A (es) 2017-06-30

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037016A UY37016A (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y métodos de su uso

Country Status (16)

Country Link
US (3) US10689396B2 (enExample)
EP (1) EP3386992B1 (enExample)
JP (2) JP7110097B2 (enExample)
KR (1) KR20180094514A (enExample)
CN (2) CN109071563A (enExample)
AR (1) AR107041A1 (enExample)
AU (1) AU2016366546B2 (enExample)
BR (1) BR112018011525B1 (enExample)
CA (1) CA3007993C (enExample)
EA (1) EA038031B1 (enExample)
IL (1) IL259862B (enExample)
JO (1) JO3793B1 (enExample)
MX (1) MX386700B (enExample)
TW (1) TWI739779B (enExample)
UY (1) UY37016A (enExample)
WO (1) WO2017100668A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003987B2 (ja) 1996-08-20 2000-01-31 篠▲崎▼ 晴彦 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
US20200079790A1 (en) * 2017-03-15 2020-03-12 Janssen Sciences Ireland Unlimited Company Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
FI3860989T3 (fi) * 2018-10-05 2023-05-25 Forma Therapeutics Inc Ubikitiinispesifisen proteaasi 30:n (usp30) inhiboiminen
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎(南京)医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
WO2006118749A1 (en) * 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
AU2006278627B2 (en) 2005-08-08 2011-08-18 Janssen Pharmaceutica, N.V. Thiazolopyrimidine kinase inhibitors
US7427625B2 (en) * 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
ES2616789T3 (es) 2006-09-22 2017-06-14 Pharmacyclics, Inc. Inhibidores de tirosina cinasa de Bruton
US8598174B2 (en) * 2008-11-12 2013-12-03 Genetech, Inc. Pyridazinones, method of making, and method of use thereof
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
KR102311329B1 (ko) 2013-03-15 2021-10-14 얀센 파마슈티카 엔.브이. 약제를 제조하기 위한 방법 및 중간체
MY179781A (en) * 2013-12-11 2020-11-13 Biogen Ma Inc Biaryl inhibitors of bruton's tyrosine kinase
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
AR107041A1 (es) 2018-03-14
BR112018011525B1 (pt) 2023-10-24
JP7471348B2 (ja) 2024-04-19
CN109071563A (zh) 2018-12-21
CN113105475A (zh) 2021-07-13
CA3007993C (en) 2024-01-16
CA3007993A1 (en) 2017-06-15
EA201891379A1 (ru) 2018-12-28
CN113105475B (zh) 2022-09-09
EA038031B1 (ru) 2021-06-25
WO2017100668A1 (en) 2017-06-15
EP3386992A1 (en) 2018-10-17
JP7110097B2 (ja) 2022-08-01
US20190284203A1 (en) 2019-09-19
US10689396B2 (en) 2020-06-23
KR20180094514A (ko) 2018-08-23
IL259862A (en) 2018-07-31
TW201734020A (zh) 2017-10-01
MX2018007084A (es) 2018-11-09
US10822348B2 (en) 2020-11-03
US20170283431A1 (en) 2017-10-05
US20190284204A1 (en) 2019-09-19
TWI739779B (zh) 2021-09-21
BR112018011525A2 (pt) 2018-11-21
IL259862B (en) 2022-04-01
JP2022141851A (ja) 2022-09-29
US10800792B2 (en) 2020-10-13
JP2018536684A (ja) 2018-12-13
AU2016366546A1 (en) 2018-05-31
MX386700B (es) 2025-03-19
EP3386992B1 (en) 2019-11-27
AU2016366546B2 (en) 2021-08-12
JO3793B1 (ar) 2021-01-31

Similar Documents

Publication Publication Date Title
UY37016A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
UY37015A (es) Inhibidores de la tirosina quinasa de bruton y métodos de su uso
MX2022010755A (es) Inhibidores de quinasa y usos de los mismos.
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
MX387487B (es) Compuestos polifluorados que actúan como inhibidores de la tirosina cinasa de bruton.
CR20150228A (es) Inhibidores de la tirosina-quinasa de bruton
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
CR20150524A (es) Compuestos de heteroarilo y sus usos
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
NI201500140A (es) Compuestos y composiciones terapéuticos
DOP2016000047A (es) Compuestos y composiciones como inhibidores de la mek
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
CR20160070A (es) Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
DOP2016000120A (es) Nuevos inhibidores de dgat2
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
DOP2015000176A (es) Compuestos de azetidiniloxifenilpirrolidina
MX376059B (es) Compuestos de pirimidina substituidos y su uso como inhibidores de la tirosina cinasa del bazo (syk).
BR112018005795A2 (pt) inibidor de quinase de egfr e método de preparação e seu uso
AR095353A1 (es) Compuesto
CR20150391A (es) Derivados 2-((4-amino-3-(3-fluoro-5-hidroxifenilo)-1h-pirazolo[3,4-d]pirimidin-1-il)metilo)-3-(2-(trifluoro-metilo)bencilo)quinazolin-4(3h)-ona y su uso como inhibidores de quinasa-3 fosfoinositida